General Information
Merck NAFLD 6024-001
A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease.
| Protocol | MK-6024-001-00 |
|---|---|
| Identifier | |
| UID | f43384ed-4116-48bb-8629-4579fec30251 |
| Status | Done - Archived |
| Phase | 2a |
| Category | Fatty Liver / Adult |
| Launch Year | 2021 |
| NCT Number | - |
| Created | 2021-04-01 15:28 |
| Last Updated | 2022-11-02 17:39 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2022-02-21 | No |
| Enrollment Open | 2021-08-16 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2021-07-12 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | No | |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | - | No | |
| Coordinator | Valenzuela, Louisito | LValenzuela | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Merck Inc. |
|---|---|
| Division | Merck Inc. |
| Team | Merck Inc. |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | IQVIA RDS Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
